Accelagen Q1 2026 Report: Expanding Talent, Technology, and Global Partnerships

With strategic growth, international partnerships, and new technology adoption, Accelagen continues to expand its global impact in clinical trials.

A StrongStart to the 2026/27 Fiscal Year

Accelagen has marked a strong start to the 2026/27 fiscal year, demonstrating steady growth, innovation, and recognition of success in previous projects. According to CEOGreg Plunkett, “The team and our delivery model continues to mature, and we’re finding better ways to do things. That’s a core value across all levels of the business.”

The company has seen an increase in staff size of approximately 30%, demonstrating their ability to attract talent even in challenging times. “I’m really proud and honoured to have so many people want to be part of our team and contribute to our mission,” Greg said.

Investing in People to Advance Patient-Centric Innovation

“It’s really about attracting the right people and giving them the tools and opportunities to excel,” Greg continued. “We want our team to contribute to the development of new technologies and new ways of maximising patient care and wellbeing.”

Many senior staff at Accelagen have direct experience in supporting patient health outcomes and processes within hospitals or private care, giving them a unique perspective on the patient experience. This allows the company to design and execute programs that keep patients front of mind. Greg added, “It is so vital going forward from regulatory approval to market launch is how the data you’re generating has a direct association to what the clinical practice will be.”

NavigatingIndustry Challenges With Agility and Insight

While the company has maintained a global perspective and has begun to see a shift in the state of play, Accelagen has not been immune to broader challenges in the clinical research sector, including global events and continued funding constraints.

“The industry will remain in flux, but our agility allows us to adapt and provide customised solutions,” Greg explained. “Understanding and reacting to data is where we create the most value for both our clients and ourselves.”

Importantly, Accelagen has maintained a focus on strengthening partnerships with existing clients, as well as with CROs from other regions. It remains clear thatinternational collaborators see value in Accelagen, and that they are competing effectively on a global scale.

ExpandingClinical Operations Into the Americas

Opportunities previously established in the US are currently seeing success, and Accelagen is also expanding into other jurisdictions, including Central and South America.This has brought with it new opportunities for alternate types of collaboration and clinical interventions.

The team has also begun to adopt and implement emerging technologies such as the ethical use ofAI. “It has become a critical add-on that many companies in the industry need to keep up with to remain competitive,” Greg added. The company is focused on determining how these products can add value not just in data quality, but also process efficiency, while remaining conscious of making the right decisions without investing in tools that don’t provide real value.

AdvancingGene Therapies and Novel Immunotherapies

Discussions around the use of gene therapy technologies have also increased this quarter with exciting clinical developments. Novel immunotherapy products have also come under investigation in areas such as autoimmune disease and oncology. “We are overjoyed by the fact that a novel treatment that we've been able to support has actually led to a positive change to their tum our, and their overall health and wellbeing,” Plunkett explained. “When you hear these sorts of stories, it reaffirms that the why is such an important part of what we do.”

Greg concluded,“It has been a foundational time. It's really been an opportunity to validate the strategies that have been put in place. To reassess our goals with a greater lens. Going forward, as we organically grow our organisation across multiple jurisdictions, it's about being able to further our partnerships and deliver more for our clients, our team, and ultimately, and most importantly, is also making that difference to patients.”

‍